Project Grant R01HL173532
Award Date
12/23/24
Completion Date
11/30/28
Dollars Obligated
$581K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Clemson, SC 29634, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a flexible bioelectronic microarchitecture that integrates a capillary-like delivery network and a tissue-like sensing network to improve cardiac tissue engineering. The $488,026 award supports the creation of a system that can efficiently deliver media and provide real-time physiological feedback to enhance the development of...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
This Project Grant award, valued at $402,911.00, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to develop a method for generating a large number of therapeutic nanovesicles (NVs) from mesenchymal stem cells (MSCs) using an extrusion process. These engineered "cell-drones" will be tested for their ability to promote tissue repair in mouse and porcine models of cardiac...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
This National Science Foundation (NSF) Engineering Program (CFDA 47.041) Project Grant award of $600,000 to Dartmouth College aims to develop methodologies for efficiently manufacturing mature human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to accelerate drug development and cardiac disease modeling. The project will employ biochip design, machine learning, developmental biology, and tissue engineering approaches to enhance the structural and functional maturity of...
This National Science Foundation (NSF) Engineering (CFDA 47.041) program grant, in the amount of $400,000, supports the development of a tissue-like, converged sensing platform for tracking excitation-contraction dynamics in cardiac organoids. The project aims to: Develop a scalable assembly strategy to fabricate an array of three-dimensional sensor structures using planar semiconducting graphene material, designed to detect both electrical and mechanical stimuli. Evaluate the multifunctional...
The National Science Foundation awarded a $450,000 Project Grant to the George Washington University under the Engineering federal grant program (CFDA 47.041) to develop scalable heart-on-a-chip platforms. Over a three-year period from April 2022 through March 2025, the University will create automated systems integrating human heart slice culture components with sensor and actuator arrays. This will enable continuous on-chip multiparametric analysis of human cardiac physiology at the cellular...
This federal Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is providing $496,367.00 to Duke University to support research on novel approaches for cardiac reprogramming. The key objectives are to: Investigate the mechanism by which a repressor complex inhibits cardiomyocyte gene expression, including studies on DNA looping and knockdown of individual repressors. Test whether targeting the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded The Johns Hopkins University a $2,249,307 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to investigate the dysregulated maturation process of pluripotent stem cell-derived cardiomyocytes (PSC-CMs) to improve their clinical viability. The research will leverage single-cell transcriptome analysis to map the gene regulatory network underlying the premature arrest of PSC-CM maturation, with...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $243,000.00 to the University of Cincinnati to develop innovative RNA biodevices that integrate CRISPR and ADAR gene-editing technologies. The goal is to enhance the efficiency and specificity of converting fibroblasts into cardiac cells, in order to advance in vivo reprogramming strategies for regenerative therapy to address...